Healthcare >> Analyst Interviews >> September 21, 2020
Pharma M&A Activity Expected to Return in 2021
Kevin Kedra is a Research Analyst with GAMCO Investors. He joined GAMCO in 2005 as a research analyst covering the health care industry. He now covers animal health, biotech and pharma for GAMCO. He graduated from the University of Pennsylvania where he received a B.S.E. in bioengineering. Profile
Word count: 3,912
TWST: Are there any specific subsectors or companies that you follow?
Mr. Kedra: There's a specific list of companies in my coverage.